Patents by Inventor Bradley M. Mitteness
Bradley M. Mitteness has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406908Abstract: Egg laying birds on egg farms are inoculated with one or more disease antigens from microbial organisms causing infectious diseases. Egg material from the eggs contain one or more avian antibodies against the microbial organisms and these avian antibodies can specifically bind and/or neutralize the microbial organisms upon consumption by individuals in a population. Egg products comprising the one or more avian antibodies are provided to individuals in the population to increase the prevalence of avian antibodies against the microbial organism in the population. The egg products are provided in a variety of formulations for protecting individuals against the disease and/or for reducing the susceptibility for acquiring the disease. Egg products effective against infections of SARS-CoV-2 in individuals and for reducing the incidence of Covid-19 are provided. Methods are provided to decrease the infection rates of infectious diseases in a population of individuals.Type: ApplicationFiled: October 18, 2021Publication date: December 21, 2023Inventors: Bradley M. Mitteness, Scott Simplot, Michelle L. Hawkins, Brian Robley, Philip Larson, Jason Hull
-
Publication number: 20230176036Abstract: Facemasks with an integrated vims detection system are described. The virus detection system is embedded in or on a acemask worn by an individual susceptible to a viral infection. The individual wears a facemask for protective purposes during work or leisure. If the individual develops a viral infection and begins discharging viral particles from mouth and/or nose, the vims detection system embedded in the facemask retains the virus particles. The virus particles are detected in an immunoassay. The virus particles in the virus detection system embedded in the facemask are detected by avian antibodies. The virus detection system in the facemask is configured to detect one or more viruses, for example, SARS-CoV-2.Type: ApplicationFiled: April 27, 2021Publication date: June 8, 2023Inventors: Scott Simplot, Bradley M. Mitteness
-
Patent number: 11365238Abstract: Neutralizing antibodies through recombinant protein expression were identified by mining antibody repertoires by high-throughput second generation sequencing. Sequencing across the majority of light and heavy chain variable regions of chicken immunoglobulins was performed at two immunological time points: a non-immune (naive) state and a post-hyperimmunization state. The mRNA was extracted from unsorted and unselected PBMC populations and identification of antigen-specific antibody sequences leveraged the significant disparity of abundance of an individual B cell clone in non-immune and immunized states. Through bioinformatic analysis, candidate amino acid sequences for variable heavy chain and light chains were identified. Recombinant polypeptides with the binding domains having the identified amino acid sequences for variable heavy chain and light chains were expressed and screened using immunoassays to confirm antigen-specificity.Type: GrantFiled: December 7, 2016Date of Patent: June 21, 2022Assignee: CAMAS INCORPORATEDInventors: Jeff Fagerlund, Bradley M. Mitteness, Connie Phillips
-
Publication number: 20210347859Abstract: Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.Type: ApplicationFiled: May 6, 2021Publication date: November 11, 2021Inventors: Scott Simplot, Bradley M. Mitteness, Michelle Hawkins, Jason Hull, Brian Robley, Philip Larson, Michael Brielmaier, Benjamin Willaert, Vergene Harkins
-
Patent number: 11168127Abstract: Compositions are described that include colostrum and/or milk replacer combined with pathogen specific avian antibodies. These pathogen specific avian antibodies include antibodies against pathogens causing infections and disease in the digestive tract as well as outside the digestive tract. Feeding regimens and methods for administering the colostrum and/or milk replacer with the pathogen specific avian antibodies result in the presence of IgY antibodies in the serum of a neonatal animal. The IgY antibody in the serum can neutralize pathogens causing infections outside of the digestive tract.Type: GrantFiled: December 1, 2016Date of Patent: November 9, 2021Assignee: CAMAS INCORPORATEDInventors: Bradley M. Mitteness, Connie Phillips, Jason Hull, Michelle Hawkins, Ky McCraken
-
Publication number: 20200407426Abstract: Neutralizing antibodies through recombinant protein expression were identified by mining antibody repertoires by high-throughput second generation sequencing. Sequencing across the majority of light and heavy chain variable regions of chicken immunoglobulins was performed at two immunological time points: a non-immune (naive) state and a post-hyperimmunization state. The mRNA was extracted from unsorted and unselected PBMC populations and identification of antigen-specific antibody sequences leveraged the significant disparity of abundance of an individual B cell clone in non-immune and immunized states. Through bioinformatic analysis, candidate amino acid sequences for variable heavy chain and light chains were identified. Recombinant polypeptides with the binding domains having the identified amino acid sequences for variable heavy chain and light chains were expressed and screened using immunoassays to confirm antigen-specificity.Type: ApplicationFiled: December 7, 2016Publication date: December 31, 2020Inventors: Jeff Fagerlund, Bradley M. Mitteness, Connie Phillips
-
Publication number: 20200121730Abstract: Compositions for reducing the emission of methane by ruminant animals are disclosed. The compositions include avian antibodies against methanogens generally found in the rumen of the animals. Egg contents of eggs from female birds inoculated with immunogenic compositions containing one or more methanogens or antigens derived from methanogens are used. The antibodies in the egg contents may be used directly without further purification, may be partially purified or purified. The compositions may be administered in drinking water or in animal feed. Administering of the anti-methanogenic composition reduces the emission of methane and increases the efficiency of feed conversion.Type: ApplicationFiled: June 19, 2018Publication date: April 23, 2020Inventor: Bradley M. Mitteness
-
Patent number: 10407494Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air.Type: GrantFiled: July 10, 2017Date of Patent: September 10, 2019Assignee: CAMAS INCORPORATEDInventor: Bradley M. Mitteness
-
Patent number: 9849175Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans.Type: GrantFiled: March 5, 2013Date of Patent: December 26, 2017Assignee: CAMAS INCORPORATEDInventors: Bradley M Mitteness, Connie Phillips
-
Publication number: 20170362308Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air.Type: ApplicationFiled: July 10, 2017Publication date: December 21, 2017Inventor: Bradley M. Mitteness
-
Patent number: 9701737Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air.Type: GrantFiled: February 10, 2004Date of Patent: July 11, 2017Assignee: CAMAS, INCORPORATEDInventors: Peter Nash, Bradley M. Mitteness
-
Patent number: 9655962Abstract: The present disclosure relates to methods and compositions administered to the lymphatic tissue of an animal to prevent or reduce the incidence of disease or disease symptoms caused by one or more disease causing entities. Tonsillar compositions can be administered to the lymphatic tissue in the oral/nasal region of the animal and can include avian antibodies from eggs of hens inoculated with one or more target disease causing entities. Treating the lymphatic tissue in the oral/nasal region with the compositions described herein can reduce or prevent the disease causing entities from adhering to the lymphatic tissue resulting in reduced infection rates. The present disclosure also relates to oral compositions that can be used to reduce or eliminate oral pathogens in animals.Type: GrantFiled: March 14, 2014Date of Patent: May 23, 2017Assignee: CAMAS INCORPORATEDInventors: Bradley M. Mitteness, Connie Phillips
-
Patent number: 8926980Abstract: Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.Type: GrantFiled: July 11, 2012Date of Patent: January 6, 2015Assignee: Camas IncorporatedInventors: Bradley M Mitteness, Connie Phillips
-
Publication number: 20140271501Abstract: The present disclosure relates to methods and compositions administered to the lymphatic tissue of an animal to prevent or reduce the incidence of disease or disease symptoms caused by one or more disease causing entities. Tonsillar compositions can be administered to the lymphatic tissue in the oral/nasal region of the animal and can include avian antibodies from eggs of hens inoculated with one or more target disease causing entities. Treating the lymphatic tissue in the oral/nasal region with the compositions described herein can reduce or prevent the disease causing entities from adhering to the lymphatic tissue resulting in reduced infection rates. The present disclosure also relates to oral compositions that can be used to reduce or eliminate oral pathogens in animals.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Camas IncorporatedInventors: Bradley M. Mitteness, Connie Phillips
-
Publication number: 20140017258Abstract: Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.Type: ApplicationFiled: July 11, 2012Publication date: January 16, 2014Applicant: Camas IncorporatedInventors: Bradley M Mitteness, Connie Phillips
-
Patent number: 8137679Abstract: A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the media in the fermentators. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody will specifically bind to the specific immunogen. When bacteria such as Lactobacillus spp. infect fermentation systems, they will further reduce alcohol conversion efficiency. Colony forming immunogens such as Lactobacillus spp.Type: GrantFiled: January 12, 2009Date of Patent: March 20, 2012Assignee: Camas IncorporatedInventors: Peter Nash, Bradley M. Mitteness
-
Publication number: 20110274701Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Applicant: Camas IncorporatedInventors: Bradley M. Mitteness, Connie Phillips
-
Patent number: 7560109Abstract: A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the rumen and intestinal tracts of host food animals. The use of antibodies against Fusobacterium necrophorum adherence antigens decreases the colonization of F. necrophorum sufficiently to reduce or eliminate the incidence of liver abscesses in the animals.Type: GrantFiled: July 12, 2007Date of Patent: July 14, 2009Assignee: Camas IncorporatedInventors: Peter Nash, Bradley M. Mitteness
-
Publication number: 20080311129Abstract: A method for the production of antibodies or microbial adherents administers is disclosed. The antibodies or microbial adherents inhibitors are administered to a patient suffering from strep throat to substantially prevent the adherents of colony-forming immunogens or haptens in the throat of the patient. Application of the antibodies should decrease the colonization of the oropharnyx, and therefore decrease symptoms of the sore inflamed throat and ultimately decrease the need for antibiotics.Type: ApplicationFiled: November 1, 2007Publication date: December 18, 2008Applicant: Camas IncorporatedInventors: Peter Nash, Bradley M. Mitteness, Michael O'Rourke
-
Publication number: 20080254038Abstract: A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the media in the fermentators. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody will specifically bind to the specific immunogen. When bacteria such as Lactobacillus spp. infect fermentation systems, they will further reduce alcohol conversion efficiency. Colony forming immunogens such as Lactobacillus spp.Type: ApplicationFiled: April 10, 2007Publication date: October 16, 2008Inventors: Peter Nash, Bradley M. Mitteness